Skip to main content
Top
Published in: Gastric Cancer 6/2017

01-11-2017 | Original Article

Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells

Authors: Mihaela Chivu-Economescu, Denisa L. Dragu, Laura G. Necula, Lilia Matei, Ana Maria Enciu, Coralia Bleotu, Carmen C. Diaconu

Published in: Gastric Cancer | Issue 6/2017

Login to get access

Abstract

Background

Keratin 17 (KRT17) was shown to be an important molecular marker for predicting the carcinogenesis, progression, and prognosis of various cancer types. Our previous studies identified KRT17 as a possible biomarker for gastric cancer by gene microarray, with an elevated expression that occurred early during tumorigenesis and increased during tumor progression. Based on these findings, we aimed to investigate KRT17 biological functions in gastric adenocarcinoma and its possible use as a rational molecular target for anticancer therapy.

Methods

We used RNA interference-mediated knockdown of KRT17 expression and analyzed the effects on cell proliferation, cell migration, and signal transduction in two gastric cell lines (AGS and NCI-N87) in vitro and on xenograft growth in vivo.

Results

The functional analysis of KRT17 knockdown cell lines showed a decreased cell proliferation (with 42.36% ± 3.2%) and migration ability (with 37.2% ± 6.2%) relative to scrambled siRNA control. The in vivo tumorigenicity on nude mice exhibited a significant decrease in tumor weight with 69.14% in xenografts obtained from AGS cells and 84.43% in xeno-NCI-N87 tumors. The analysis on KRT17 knockdown outcome on intracellular signaling identifies AKT/mTOR as the main affected pathway that sustains proliferation and survival, and also the AMPKα1/CREB pathway that was recently shown to induce organ protection and antiinflammatory response.

Conclusions

Our results highlight KRT17 as a possible biomarker in gastric cancer promoting tumor growth, motility, and invasion, and suggest that KRT17 can be a valuable molecular target for development of anti-gastric cancer-specific therapies.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.CrossRef
2.
go back to reference Xu ZY, Tang JN, Xie HX, Du YA, Huang L, Yu PF, et al. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci. 2015;11:284–94.CrossRefPubMedPubMedCentral Xu ZY, Tang JN, Xie HX, Du YA, Huang L, Yu PF, et al. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci. 2015;11:284–94.CrossRefPubMedPubMedCentral
3.
go back to reference Bouvier AM, Sant M, Verdecchia A, Forman D, Damhuis R, Willem Coebergh J, et al. What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer. 2010;46:1086–92.CrossRefPubMed Bouvier AM, Sant M, Verdecchia A, Forman D, Damhuis R, Willem Coebergh J, et al. What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer. 2010;46:1086–92.CrossRefPubMed
4.
go back to reference Chivu Economescu M, Necula LG, Dragu D, Badea L, Dima SO, Tudor S, et al. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology. 2010;57:1453–64.PubMed Chivu Economescu M, Necula LG, Dragu D, Badea L, Dima SO, Tudor S, et al. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology. 2010;57:1453–64.PubMed
5.
go back to reference Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011;30:127–38.CrossRefPubMed Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011;30:127–38.CrossRefPubMed
6.
go back to reference Kim S, Wong P, Coulombe PA. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature (Lond). 2006;441:362–5.CrossRef Kim S, Wong P, Coulombe PA. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature (Lond). 2006;441:362–5.CrossRef
7.
go back to reference Troy TC, Turksen K. Commitment of embryonic stem cells to an epidermal cell fate and differentiation in vitro. Dev Dyn. 2005;232:293–300.CrossRefPubMed Troy TC, Turksen K. Commitment of embryonic stem cells to an epidermal cell fate and differentiation in vitro. Dev Dyn. 2005;232:293–300.CrossRefPubMed
9.
go back to reference van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991–6.CrossRefPubMedPubMedCentral van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991–6.CrossRefPubMedPubMedCentral
10.
go back to reference Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.CrossRefPubMedPubMedCentral Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.CrossRefPubMedPubMedCentral
11.
go back to reference Wang YF, Lang HY, Yuan J, Wang J, Wang R, Zhang XH, et al. Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer. Tumour Biol. 2013;34:1685–9.CrossRefPubMed Wang YF, Lang HY, Yuan J, Wang J, Wang R, Zhang XH, et al. Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer. Tumour Biol. 2013;34:1685–9.CrossRefPubMed
12.
go back to reference Escobar-Hoyos LF, Yang J, Zhu J, Cavallo JA, Zhai H, Burke S, et al. Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker. Mod Pathol. 2014;27:621–30.CrossRefPubMed Escobar-Hoyos LF, Yang J, Zhu J, Cavallo JA, Zhai H, Burke S, et al. Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker. Mod Pathol. 2014;27:621–30.CrossRefPubMed
13.
go back to reference Ide M, Kato T, Ogata K, Mochiki E, Kuwano H, Oyama T. Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. Ann Surg Oncol. 2012;19:3506–14.CrossRefPubMed Ide M, Kato T, Ogata K, Mochiki E, Kuwano H, Oyama T. Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. Ann Surg Oncol. 2012;19:3506–14.CrossRefPubMed
14.
go back to reference Obermajer N, Doljak B, Kos J. Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. Mol Cancer. 2009;8:88.CrossRefPubMedPubMedCentral Obermajer N, Doljak B, Kos J. Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. Mol Cancer. 2009;8:88.CrossRefPubMedPubMedCentral
15.
go back to reference Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006;34:322–33.CrossRefPubMedPubMedCentral Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006;34:322–33.CrossRefPubMedPubMedCentral
16.
go back to reference Omi K, Tokunaga K, Hohjoh H. Long-lasting RNAi activity in mammalian neurons. FEBS Lett. 2004;558:89–95.CrossRefPubMed Omi K, Tokunaga K, Hohjoh H. Long-lasting RNAi activity in mammalian neurons. FEBS Lett. 2004;558:89–95.CrossRefPubMed
17.
go back to reference Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–9.CrossRefPubMed Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–9.CrossRefPubMed
18.
go back to reference Wiksten JP, Lundin J, Nordling S, Kokkola A, von Boguslawski K, Haglund C. The prognostic value of p27 in gastric cancer. Oncology. 2002;63:180–4.CrossRefPubMed Wiksten JP, Lundin J, Nordling S, Kokkola A, von Boguslawski K, Haglund C. The prognostic value of p27 in gastric cancer. Oncology. 2002;63:180–4.CrossRefPubMed
19.
go back to reference Calik M, Demirci E, Altun E, Calik I, Gundogdu OB, Gursan N, et al. Clinicopathological importance of Ki-67, p27, and p53 expression in gastric cancer. Turk J Med Sci. 2015;45:118–28.CrossRefPubMed Calik M, Demirci E, Altun E, Calik I, Gundogdu OB, Gursan N, et al. Clinicopathological importance of Ki-67, p27, and p53 expression in gastric cancer. Turk J Med Sci. 2015;45:118–28.CrossRefPubMed
20.
go back to reference Escobar-Hoyos LF, Shah R, Roa-Pena L, Vanner EA, Najafian N, Banach A, et al. Keratin-17 promotes p27KIP1 nuclear export and degradation and offers potential prognostic utility. Cancer Res. 2015;75:3650–62.CrossRefPubMed Escobar-Hoyos LF, Shah R, Roa-Pena L, Vanner EA, Najafian N, Banach A, et al. Keratin-17 promotes p27KIP1 nuclear export and degradation and offers potential prognostic utility. Cancer Res. 2015;75:3650–62.CrossRefPubMed
21.
go back to reference Thornton CC, Al-Rashed F, Calay D, Birdsey GM, Bauer A, Mylroie H, et al. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis. 2016;75:439–48.CrossRefPubMed Thornton CC, Al-Rashed F, Calay D, Birdsey GM, Bauer A, Mylroie H, et al. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis. 2016;75:439–48.CrossRefPubMed
22.
go back to reference Escobar DA, Botero-Quintero AM, Kautza BC, Luciano J, Loughran P, Darwiche S, et al. Adenosine monophosphate-activated protein kinase activation protects against sepsis-induced organ injury and inflammation. J Surg Res. 2015;194:262–72.CrossRefPubMed Escobar DA, Botero-Quintero AM, Kautza BC, Luciano J, Loughran P, Darwiche S, et al. Adenosine monophosphate-activated protein kinase activation protects against sepsis-induced organ injury and inflammation. J Surg Res. 2015;194:262–72.CrossRefPubMed
23.
go back to reference Rexer BN, Ghosh R, Arteaga CL. Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin Cancer Res. 2009;15:4518–20.CrossRefPubMed Rexer BN, Ghosh R, Arteaga CL. Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin Cancer Res. 2009;15:4518–20.CrossRefPubMed
24.
go back to reference Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72:3228–37.CrossRefPubMedPubMedCentral Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72:3228–37.CrossRefPubMedPubMedCentral
25.
go back to reference Shi XH, Liang ZY, Ren XY, Liu TH. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther. 2009;16:227–36.PubMed Shi XH, Liang ZY, Ren XY, Liu TH. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther. 2009;16:227–36.PubMed
26.
go back to reference Conacci-Sorrell M, Zhurinsky J, Ben-Ze’ev Ben-Ze’ev. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest. 2002;109:987–91.CrossRefPubMedPubMedCentral Conacci-Sorrell M, Zhurinsky J, Ben-Ze’ev Ben-Ze’ev. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest. 2002;109:987–91.CrossRefPubMedPubMedCentral
28.
go back to reference Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.CrossRefPubMed Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.CrossRefPubMed
Metadata
Title
Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells
Authors
Mihaela Chivu-Economescu
Denisa L. Dragu
Laura G. Necula
Lilia Matei
Ana Maria Enciu
Coralia Bleotu
Carmen C. Diaconu
Publication date
01-11-2017
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 6/2017
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-017-0712-y

Other articles of this Issue 6/2017

Gastric Cancer 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine